A Doctor Tested a New Treatment on Himself, Now it's Saving Other Lives
Penn Medicine physician, David Fajgenbaum, developed a treatment for Castleman disease, and tested on himself. Clinical trials will begin in the coming weeks.
Sep 5, 2019 | IFL Science
When Dr David Fajgenbaum was diagnosed with Castleman disease his prospects looked so grim he once had the last rites administered. Yet Fajgenbaum found a possible molecular basis for his condition and tested a potential treatment on himself. Five years later he remains in remission and is first author on a paper describing the successful treatment on himself and others.
Castleman disease is the name given to a group of similar-appearing inflammatory disorders. Some of these are mild enough to be hard to distinguish from the flu, but the most serious, idiopathic multicentric Castleman disease (iMCD) can cause multiple organ failure. More than a third of iMCD patients die within five years of diagnosis.
Siltuximab, the only currently approved drug for (iMCD), induces dramatic remission in up to half of patients, but does nothing for others. As one of those who didn’t benefit, Fajgenbaum tried chemotherapy, experiencing terrible side-effects, but his sickness rapidly returned after each course of treatment and he nearly died five times.
As a medical student at the University of Pennsylvania, however, Fajgenbaum had the opportunity to investigate the molecular basis of his own disease. In the Journal of Clinical Investigation, he describes identifying unusually high mammalian target of rapamycin (mTOR) signaling in samples from his lymph nodes compared to those from healthy people. MTOR acts as a stage in a cell regulation pathway whose malfunction has been implicated in a number of important diseases.
Sirolimus is a mTOR inhibitor already approved to prevent rejection of transplanted kidneys. Fajgenbaum took it and his symptoms went into remission. “I realized that if I didn’t dedicate the rest of my life to trying to cure this disease, that no one else was going to do it,” he told the Huffington Post in 2017 as it was starting to become clear the process had worked. “I didn’t have many more shots.” Fafgenbaum’s book on his experiences can be preordered before September release.
Following this success, colleagues gave the same treatment to another two patients whose iMCD had also not responded to existing treatments.
At the time of submitting the paper, Fajgenbaum had been in remission for five and a half years, while the other two patients had each gone for 19 months without the disease coming back.
A clinical trial is about to open at the Universities of Pennsylvania and Arkansas, offering hope to those who have not responded to siltuximab and live close enough to either location to take part.
The implications of Fajgenbaum taking the proverb “physician heal thyself” literally could be much wider, however. Recent work has raised the possibility mTOR inhibition could be a lifesaver for what is currently the least treatable form of breast cancer.
More broadly still, the story emphasizes the same cellular pathway can cause different diseases depending on the organ in which it malfunctions. “This highlights the potential for the approximately 1,500 drugs already approved for one condition to also be treatments or cures for the 7,000 diseases with no or insufficient treatment options like ALS and many pediatric cancers,” Fajgenbuam said.
TRNDS 2019
University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642
Date: Friday, September 13
Time: 7:30 am – 4:00pm
TRNDS News
Sign-up for TRNDS updates and rare disease news
-
New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
-
Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
-
NIH launches 5-year, $10 million study on acute flaccid myelitis
-
Study refines ALS risk among first-degree relatives of patients with disease
-
NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
-
Speeding Up Drug Discovery for Brain Diseases
-
NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
-
Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
-
(Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
-
Meet TRNDS 2019 Speaker PJ Brooks
-
Rare Pediatric Disease PRVs: FDA Updates Guidance
-
Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
-
C-Path and NORD Collaborate to Launch Rare Disease Data Platform
-
Meet TRNDS Speaker Tauna Batiste
-
HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
-
Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
-
'Dr. Google' Helps Some Patients Diagnose a Rare Disease
-
Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
-
Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
-
Netflix's Medical Investigation Docuseries 'Diagnosis'
-
NIH All of Us Project Tops 270,000 Sign-ups
-
FDA Cancer Office Taps Syapse for Real-world Evidence Development
-
Gene Linked to Rare Neurological Disorder May Play a Role in Alzheimer’s
-
Gene Therapy Developers Issue Principles for Human Genome Editing
-
Forget Single Genes: CRISPR Now Cuts & Splices Whole Chromosomes
-
TRNDS Speaker Benjamin Schlatka, MC10
-
TRNDS Speaker Danielle Edwards, Jett Foundation
-
His daughter has a rare disorder. He’s developing a novel gene therapy.
-
A Doctor Tested a New Treatment on Himself, Now it's Saving Other Lives
-
Study Presents Clinical, Genetic Landscape of Pompe Disease
Room Block
Hilton Garden Inn
Rochester/University
Medical Center
30 Celebration Drive
Rochester, NY 14620
Phone: 585-424-4404
TRNDS Rate: $149/night